| pubmed-article:6333383 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6333383 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:6333383 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
| pubmed-article:6333383 | lifeskim:mentions | umls-concept:C0030005 | lld:lifeskim |
| pubmed-article:6333383 | lifeskim:mentions | umls-concept:C0301872 | lld:lifeskim |
| pubmed-article:6333383 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:6333383 | pubmed:dateCreated | 1984-12-18 | lld:pubmed |
| pubmed-article:6333383 | pubmed:abstractText | Antibodies, raised in CBA and C3H mice, to a hapten 2-furyloxazolone (furyl Ox) have a strange (heteroclitic) fine-specificity, having a higher affinity for the chemical analogue 2-styryloxazolone (styryl Ox) than for furyl Ox. Other mouse strains were found to produce 'normal' anti-furyl Ox antibodies, and the heteroclicity was inherited as an Igh allotype-linked trait (Mäkelä, Matoso-Ferreira & Kaartinen 1983). Hapten-specific cytolytic T lymphocytes (CTL) were generated by painting cyclophosphamide-treated mice with chemically reactive haptens, furyl Ox and styryl Ox, and their fine-specificity was investigated. Cytolytic cells generated in this way were 'homoclitic' in all cases, showing a preference for targets coupled with the homologous haptens (the immunogens). | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6333383 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6333383 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6333383 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6333383 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:6333383 | pubmed:issn | 0019-2805 | lld:pubmed |
| pubmed-article:6333383 | pubmed:author | pubmed-author:Matoso-Ferrei... | lld:pubmed |
| pubmed-article:6333383 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6333383 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:6333383 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6333383 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6333383 | pubmed:pagination | 451-6 | lld:pubmed |
| pubmed-article:6333383 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:6333383 | pubmed:meshHeading | pubmed-meshheading:6333383-... | lld:pubmed |
| pubmed-article:6333383 | pubmed:meshHeading | pubmed-meshheading:6333383-... | lld:pubmed |
| pubmed-article:6333383 | pubmed:meshHeading | pubmed-meshheading:6333383-... | lld:pubmed |
| pubmed-article:6333383 | pubmed:meshHeading | pubmed-meshheading:6333383-... | lld:pubmed |
| pubmed-article:6333383 | pubmed:meshHeading | pubmed-meshheading:6333383-... | lld:pubmed |
| pubmed-article:6333383 | pubmed:meshHeading | pubmed-meshheading:6333383-... | lld:pubmed |
| pubmed-article:6333383 | pubmed:meshHeading | pubmed-meshheading:6333383-... | lld:pubmed |
| pubmed-article:6333383 | pubmed:meshHeading | pubmed-meshheading:6333383-... | lld:pubmed |
| pubmed-article:6333383 | pubmed:meshHeading | pubmed-meshheading:6333383-... | lld:pubmed |
| pubmed-article:6333383 | pubmed:meshHeading | pubmed-meshheading:6333383-... | lld:pubmed |
| pubmed-article:6333383 | pubmed:meshHeading | pubmed-meshheading:6333383-... | lld:pubmed |
| pubmed-article:6333383 | pubmed:meshHeading | pubmed-meshheading:6333383-... | lld:pubmed |
| pubmed-article:6333383 | pubmed:meshHeading | pubmed-meshheading:6333383-... | lld:pubmed |
| pubmed-article:6333383 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6333383 | pubmed:articleTitle | Fine-specificity of the immune response to oxazolones. IV. Furyloxazolone-specific cytolytic T lymphocytes (unlike antibodies) are not heteroclitic. | lld:pubmed |
| pubmed-article:6333383 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6333383 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
